Immunogenic epitopes for fibroblast growth factors 5 (FGF-5)
AssigneeThe Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
InventorsKen-Ichi Hanada, James Yang, Donna Perry-Lalley
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to peptides for use in immunotherapy of FGF-5 expressing tumors. In one example, the peptide is an HLA-A3 epitope (such as NTYASPRFK). In another example, the peptide is an HLA-A2 epitope (such as MLSVLEIFAV). Methods are provided for using such peptides (and corresponding nucleic acid molecules), and variants, fragments or fusions thereof, to stimulate an immune response in a subject. The peptides (and corresponding nucleic acid molecules) disclosed herein can be formulated into pharmaceutical composition for administration to a subject.
Claims39
A purified immunogenic peptide comprising Tyr-Ala-(A3)-(A4)-Arg-Phe wherein A3 is Ala or Ser and A4 is Ala or Pro (SEQ ID NO:
- 39), wherein the peptide is at least eight amino acids in length.
A purified immunogenic peptide comprising at least 78% sequence identity to SEQ ID NO:
- 26, wherein the peptide is at least nine amino acids in length.
A purified immunogenic peptide comprising at least 80% sequence identity to SEQ ID NO:
- 32, wherein the peptide is at least 10 amino acids in length.
A method of stimulating a cytotoxic T cell response against a RCC, comprising:
- administering to a subject having RCC a therapeutically effective amount of SEQ ID NO:
- 26 or 32 sufficient to stimulate the T cell to react with a cell of the RCC.
Dependencies are inferred from the claim text.